PUBLISHER: The Business Research Company | PRODUCT CODE: 1455158
PUBLISHER: The Business Research Company | PRODUCT CODE: 1455158
The treatment of acquired hemophilia refers to therapeutic approaches utilized to manage and address this non-hereditary bleeding disorder. It arises from a mutation or alteration in one of the genes responsible for producing clotting factor proteins crucial for blood clot formation. The treatment involves various strategies, including controlling bleeding episodes and eliminating inhibitors that target clotting factors.
The primary treatments for acquired hemophilia include on-demand and prophylaxis. On-demand treatment involves administering clotting factor replacement therapy only in response to clinically significant bleeding. Hospitals, clinics, and other end users prescribe this treatment for hemophilia A, hemophilia B, hemophilia C, and other related conditions.
The acquired hemophilia treatment market research report is one of a series of new reports from The Business Research Company that provides acquired hemophilia treatment market statistics, including acquired hemophilia treatment industry global market size, regional shares, competitors with an acquired hemophilia treatment market share, detailed acquired hemophilia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acquired hemophilia treatment industry. This acquired hemophilia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acquired hemophilia treatment market size has grown strongly in recent years. It will grow from $11.47 billion in 2023 to $12.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed during the historical period can be attributed to factors such as the increasing aging population, improved diagnostics and awareness, expansion of the patient pool, collaborative research initiatives, and regulatory support and approvals.
The acquired hemophilia treatment market size is expected to see strong growth in the next few years. It will grow to $14.88 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The expansion anticipated in the forecast period can be attributed to factors such as the growing global population, increased healthcare investments, trends in personalized medicine, international collaborations in research, rising healthcare awareness, and regulatory support for orphan drugs. Major trends in the forecast period include advancements in monitoring and diagnostic technologies, collaboration for patient support programs, research on gene therapy approaches, increased utilization of immune tolerance induction, and the adoption of telemedicine for remote consultations.
The anticipated growth in the acquired hemophilia treatment market is expected to be driven by an increasing number of ongoing clinical trials. Clinical trials, which involve research studies with human participants, play a crucial role in evaluating the safety and effectiveness of new medical treatments for acquired hemophilia. These trials contribute to advancing research, enhancing patient outcomes, and establishing effective therapeutic interventions. As of October 2023, according to ClinicalTrials.gov, the number of registered studies globally increased from 437,523 in 2022 to 468,457 across all 50 states in the United States and 221 countries. The U.S. alone accounted for 143,613 studies (31% of the total), while non-U.S. locations registered 251,159 studies (54% of the total). Hence, the growing number of ongoing clinical trials is a significant driver for the acquired hemophilia treatment market.
The growth of the acquired hemophilia treatment market is expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, representing the total amount spent on healthcare goods and services within a specific period, plays a crucial role in facilitating access to advanced therapies, medical interventions, and comprehensive care for acquired hemophilia. In March 2023, the American Medical Association reported that healthcare spending in the United States reached $4.3 trillion in 2021, with a per capita expenditure of $12,914. Physician spending increased by 3.8% on average, while hospital services (4.5%) and clinical services (6.6%) experienced larger growth rates. Therefore, the rising healthcare expenditure drives the acquired hemophilia treatment market.
The high cost associated with bypassing agents may act as a hindrance to the market's growth during the forecast period. The elevated cost of these agents may limit access to essential treatment for individuals with acquired hemophilia, potentially leading to delayed or suboptimal care and increased risks of severe bleeding episodes. For example, a study by the National Library of Medicine in June 2023 revealed that the average annual healthcare cost for patients ranged from $213,874 to $869,940 in 2021, driven mainly by factors such as Hemophilia A (Factor VIII Deficiency), bypassing agents, and emicizumab. Thus, the high cost of bypassing agents poses a challenge to the growth of the acquired hemophilia treatment market.
Major companies in the acquired hemophilia treatment market are actively focused on obtaining approvals for drugs with additional measures to strengthen their market position. Drug approvals that include routine prophylaxis are increasing, addressing the need for more effective and safer treatment options. For instance, in June 2022, Chugai Pharmaceutical received extended approval from Japan's Ministry of Health, Labor and Welfare to expand the use of Hemlibra (emicizumab) for routine prophylaxis in acquired hemophilia A patients, aiming to reduce or minimize the occurrence of bleeds. This bispecific antibody simultaneously targets factor IX and factor X binding sites, enhancing the control of bleeding in patients.
In June 2023, Baudax Bio. completed the acquisition of TeraImmune Inc., an advanced research company based in the U.S., for an undisclosed amount. This strategic move aimed to combine TeraImmune's scientific expertise with Baudax Bio.'s proficiency in executing clinical development programs. The acquisition incorporated TeraImmune's TI-168 asset, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to neutralize clotting factor VIII (FVIII) inhibitors in Hemophilia A patients. TeraImmune Inc. contributed valuable advancements in the field of treatments for hemophilia.
Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation
North America was the largest region in the acquired hemophilia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the acquired hemophilia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acquired hemophilia treatment market consists of revenues earned by entities by providing services such as eradication of inhibitors, individualized therapeutic approach, multidisciplinary approach, and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired hemophilia treatment market also includes sales of immunosuppressive agents including cyclosporine A, and azathioprine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acquired Hemophilia Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acquired hemophilia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acquired hemophilia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired hemophilia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.